United States - English - NLM (National Library of Medicine)

amneal-agila, llc - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine is indicated for combination antiretroviral treatment of hiv-1 infection in adults and in pediatrics patients 15 days and older [see clinical studies (14.1) , (14.2) ]. additional important information regarding the use of nevirapine for the treatment of hiv-1 infection: •based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with cd4+ cell counts greater than 250 cells/mm3 or in adult males with cd4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see boxed warning and warnings and precautions (5.1) ]. •the 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see dosage and administration (2.4) and warnings and precautions (5.2) ]. •if rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. the 200 mg once-daily dosing regimen should not b

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 400 mg - viramune xr is indicated for use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in children 6 to less than 18 years of age [see clinical studies (14.1, 14.2) ]. additional important information regarding the use of viramune xr for the treatment of hiv-1 infection: - based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with cd4+ cell counts greater than 250 cells/mm3 or in adult males with cd4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see boxed warning and warnings and precautions (5.1) ]. - the 14-day lead-in period with immediate-release viramune dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see dosage and administration (2.5) and warnings and precautions (5.2) ]. - if rash persists beyond the 14-day lead-in period with immediate-release viramune, do not begin dosing with

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nevirapine, quantity: 400 mg - tablet, modified release - excipient ingredients: methylcellulose; iron oxide yellow; hypromellose; magnesium stearate - nevirapine modified release tablet in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years.,modified release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nevirapine, quantity: 400 mg - tablet, modified release - excipient ingredients: methylcellulose; iron oxide yellow; hypromellose; magnesium stearate - nevirapine modified release tablet in combination with antiretroviral agents is indicated for the treatment of hiv-1 infection in adults and children over the age of three years.,modified release tablets are not suitable for the 14 day lead-in period for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.,resistant virus emerges rapidly when nevirapine is administered as monotherapy or in dual combination therapy with an antiretroviral agent. therefore, nevirapine should always be administered in combination with at least two additional antiretroviral agents.

Malta - English - Medicines Authority

accord healthcare limited - nevirapine, anhydrous - prolonged-release tablet - nevirapine, anhydrous 400 mg - antivirals for systemic use

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - nevirapine, anhydrous - prolonged-release tablet - nevirapine, anhydrous 400 mg - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use